CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia
CollPlant Biotechnologies (NASDAQ: CLGN) has announced the expansion of distribution channels for its VergenixSTR product in Europe and Asia. The company has signed new distribution agreements with companies in the Netherlands, Turkey, and India, covering territories including Benelux, Spain, India, and Turkey.
The first shipment to the Benelux and Spain distributor, which specializes in orthopedic medical device sales, was made in February 2025. The Turkish and Indian distributors are finalizing regulatory processes with local authorities, aiming to begin sales in 2025.
VergenixSTR, based on CollPlant's rhCollagen technology, is designed to treat tendinopathy in various tendons including elbow, rotator cuffs, patellar, Achilles, and hand tendons. The product combines cross-linked rhCollagen with Platelet-rich plasma (PRP) to form a gel matrix that enables localized sustained release of growth factors at injury sites for optimal healing.
CollPlant Biotechnologies (NASDAQ: CLGN) ha annunciato l'espansione dei canali di distribuzione per il suo prodotto VergenixSTR in Europa e Asia. L'azienda ha firmato nuovi accordi di distribuzione con aziende nei Paesi Bassi, in Turchia e in India, coprendo territori tra cui Benelux, Spagna, India e Turchia.
La prima spedizione al distributore del Benelux e della Spagna, specializzato nella vendita di dispositivi medici ortopedici, è stata effettuata a febbraio 2025. I distributori turchi e indiani stanno finalizzando i processi normativi con le autorità locali, con l'obiettivo di iniziare le vendite nel 2025.
VergenixSTR, basato sulla tecnologia rhCollagen di CollPlant, è progettato per trattare la tendinopatia in vari tendini, tra cui quelli del gomito, delle spalle, patellari, achillei e dei manoscritti. Il prodotto combina rhCollagen reticolato con plasma ricco di piastrine (PRP) per formare una matrice gelificata che consente il rilascio localizzato e sostenuto di fattori di crescita nei siti di lesione per una guarigione ottimale.
CollPlant Biotechnologies (NASDAQ: CLGN) ha anunciado la expansión de los canales de distribución para su producto VergenixSTR en Europa y Asia. La empresa ha firmado nuevos acuerdos de distribución con compañías en los Países Bajos, Turquía e India, cubriendo territorios que incluyen Benelux, España, India y Turquía.
El primer envío al distribuidor de Benelux y España, especializado en la venta de dispositivos médicos ortopédicos, se realizó en febrero de 2025. Los distribuidores turcos e indios están finalizando los procesos regulatorios con las autoridades locales, con el objetivo de comenzar las ventas en 2025.
VergenixSTR, basado en la tecnología rhCollagen de CollPlant, está diseñado para tratar la tendinopatía en varios tendones, incluyendo los del codo, manguitos rotadores, patelares, de Aquiles y de la mano. El producto combina rhCollagen entrecruzado con plasma rico en plaquetas (PRP) para formar una matriz de gel que permite la liberación sostenida y localizada de factores de crecimiento en los sitios de lesión para una curación óptima.
CollPlant Biotechnologies (NASDAQ: CLGN)는 유럽과 아시아에서 VergenixSTR 제품의 유통 채널 확장을 발표했습니다. 이 회사는 네덜란드, 터키 및 인도의 기업들과 새로운 유통 계약을 체결하여 벨기에, 네덜란드, 룩셈부르크, 스페인, 인도 및 터키를 포함한 지역을 포괄합니다.
정형외과 의료 기기 판매를 전문으로 하는 벨기에 및 스페인 유통업체에 대한 첫 번째 배송은 2025년 2월에 이루어졌습니다. 터키 및 인도 유통업체는 현지 당국과의 규제 프로세스를 마무리하고 있으며, 2025년 판매를 시작할 계획입니다.
CollPlant의 rhCollagen 기술을 기반으로 한 VergenixSTR는 팔꿈치, 회전근개, 슬개골, 아킬레스 및 손의 힘줄을 포함한 다양한 힘줄의 힘줄병을 치료하도록 설계되었습니다. 이 제품은 교차 결합된 rhCollagen과 혈소판 풍부 혈장(PRP)을 결합하여 부상 부위에서 성장 인자를 최적의 치유를 위해 국소적으로 지속적으로 방출할 수 있는 젤 매트릭스를 형성합니다.
CollPlant Biotechnologies (NASDAQ: CLGN) a annoncé l'expansion de ses canaux de distribution pour son produit VergenixSTR en Europe et en Asie. L'entreprise a signé de nouveaux accords de distribution avec des sociétés aux Pays-Bas, en Turquie et en Inde, couvrant des territoires tels que le Benelux, l'Espagne, l'Inde et la Turquie.
Le premier envoi au distributeur du Benelux et d'Espagne, spécialisé dans la vente de dispositifs médicaux orthopédiques, a été effectué en février 2025. Les distributeurs turcs et indiens finalisent actuellement les processus réglementaires avec les autorités locales, visant à commencer les ventes en 2025.
VergenixSTR, basé sur la technologie rhCollagen de CollPlant, est conçu pour traiter la tendinopathie dans divers tendons, y compris ceux du coude, de la coiffe des rotateurs, patellaires, d'Achille et de la main. Le produit combine le rhCollagen réticulé avec du plasma riche en plaquettes (PRP) pour former une matrice gélifiée qui permet une libération localisée et soutenue des facteurs de croissance sur les sites de blessure pour une guérison optimale.
CollPlant Biotechnologies (NASDAQ: CLGN) hat die Erweiterung der Vertriebskanäle für sein Produkt VergenixSTR in Europa und Asien bekannt gegeben. Das Unternehmen hat neue Vertriebsvereinbarungen mit Firmen in den Niederlanden, der Türkei und Indien unterzeichnet, die Gebiete wie Benelux, Spanien, Indien und die Türkei abdecken.
Die erste Lieferung an den Distributor für Benelux und Spanien, der auf den Verkauf von orthopädischen Medizinprodukten spezialisiert ist, erfolgte im Februar 2025. Die türkischen und indischen Distributoren finalisieren derzeit die regulatorischen Prozesse mit den lokalen Behörden, mit dem Ziel, 2025 mit dem Verkauf zu beginnen.
VergenixSTR, das auf der rhCollagen-Technologie von CollPlant basiert, ist zur Behandlung von Tendinopathien in verschiedenen Sehnen, einschließlich Ellenbogen, Rotatorenmanschette, Patella, Achillessehne und Handsehnen, konzipiert. Das Produkt kombiniert vernetztes rhCollagen mit plättchenreichem Plasma (PRP), um eine Gelmatrix zu bilden, die eine lokal begrenzte und nachhaltige Freisetzung von Wachstumsfaktoren an den Verletzungsstellen für eine optimale Heilung ermöglicht.
- Expansion into new European and Asian markets through distribution agreements
- First product shipment already completed to Benelux and Spain in February 2025
- Strategic partnership with Allergan (AbbVie) for dermal and soft tissue fillers established in 2021
- Pending regulatory approvals required in Turkey and India before sales can commence
- Company has history of significant losses as mentioned in forward-looking statements
- Requires additional capital raising which may not be obtained on acceptable terms
Insights
The expansion of VergenixSTR's distribution network marks a strategic pivot in CollPlant's commercialization efforts, targeting key markets with significant orthopedic treatment demands. The selection of distributors with specialized orthopedic expertise, particularly in the Benelux and Spain regions, suggests a sophisticated market entry strategy that could accelerate adoption among medical professionals.
The product's technological differentiation lies in its unique matrix-forming capabilities that enable controlled release of growth factors - a critical feature for optimal tendon healing. This addresses a significant limitation of traditional PRP treatments where growth factors typically dissipate rapidly from the injection site. The sustained release mechanism potentially offers superior therapeutic outcomes in treating various tendinopathies, from tennis elbow to Achilles tendon injuries.
The market opportunity is particularly compelling in the selected territories:
- Benelux and Spain represent mature medical device markets with established reimbursement pathways
- Turkey serves as a strategic gateway to Middle Eastern markets with a growing medical tourism sector
- India offers vast scale potential with its large population and expanding healthcare infrastructure
The regulatory progression in Turkey and India, with anticipated 2025 launch, indicates a well-structured expansion timeline. The company's ability to secure distributors with specific medical device expertise suggests thorough due diligence in partner selection, which is important for successful market penetration in these diverse healthcare systems.
REHOVOT,
The new distributor for Benelux and
Yehiel Tal, Chief Executive Officer of CollPlant, commented, "As we expand the distribution network in the
About Vergenix STR
VergenixSTR is a soft tissue repair matrix that combines cross-linked rhCollagen with Platelet-rich plasma, or PRP, a concentrated blood plasma that contains high levels of platelets, a critical component of the healing process. Platelets contain growth factors that are responsible for stimulating tissue generation and repair, including soft tissue repair, bone regeneration, development of new blood vessels, and stimulation of the wound healing process. VergenixSTR serves as a scaffold to support cell proliferation and the release of growth factors. The product is injected into the affected area and forms a viscous gel matrix which serves as a temporary reservoir for PRP in the vicinity of a tendon injury site, holding the platelet concentrate in place at the injured area. The matrix formed has the capabilities to activate the platelets in PRP, thereby releasing growth factors in a controlled manner and controlled biodegradation time, enabling optimal healing.
About CollPlant Biotechnologies
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future such as expectations regarding the market potential of VergenixSTR. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results, including with respect to the Company's dermal filler product; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com
Photo: https://mma.prnewswire.com/media/2626017/COLLPLANT_VergenixSTR.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-expands-distribution-for-its-vergenixstr-product-in-europe-and-asia-302383282.html
SOURCE CollPlant
FAQ
What new markets will VergenixSTR expand into through CollPlant's (CLGN) latest distribution agreements?
When did CollPlant (CLGN) make its first VergenixSTR shipment to the Benelux distributor?
What medical conditions does CollPlant's VergenixSTR treat?
How does CollPlant's (CLGN) VergenixSTR technology work?
When are VergenixSTR sales expected to begin in Turkey and India?
